Plain-English translation of NCT04629547 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are investigating whether a medication called suvorexant can help prevent Alzheimer's disease by reducing the buildup of harmful proteins in the brain. The study focuses on older adults who have sleep problems but no signs of memory loss yet. By improving sleep, the medication may slow down brain changes that lead to Alzheimer's disease.
Poor sleep has been linked to the buildup of proteins in the brain that contribute to Alzheimer's disease. This trial explores whether treating sleep problems with this medication might help prevent or delay the onset of Alzheimer's disease in people at risk.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the study medication or a placebo (a pill with no active ingredient) once daily at bedtime for 18 to 24 months. Half of the 200 participants will receive the actual medication, and half will receive placebo. During the study, you will have regular visits to check your health, provide blood samples to measure protein levels in your blood, and complete sleep and cognitive assessments.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Sponsor
Washington University School of Medicine
Collaborators
Good Ventures, Merck Sharp & Dohme LLC
Enrollment target
~200 participants
Started
May 2022
Primary completion
May 2028
Age range
65 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Cristina Toedebusch, BS
Washington Univeristy School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.